Why the study?
Few studies with large sample sizes are available regarding patients with Wellens' syndrome, leaving its current incidence, risk factors, clinical presentation, and long-term outcomes unclear.
Does the presence of Wellens' syndrome increase the risk of cardiac death or MACCE in NSTE-ACS patients with culprit LAD vessels undergoing angioplasty?
Does the presence of Wellens' syndrome increase the risk of cardiac death or MACCE in NSTE-ACS patients with culprit LAD vessels undergoing angioplasty?
In NSTE-ACS patients with culprit LAD lesions undergoing angioplasty, the presence of Wellens' syndrome was not associated with an increased risk of long-term cardiac death or MACCE compared to those without Wellens' syndrome.
Answers are grounded in this paper and cite their sources.
May not elevate long-term MACCE or cardiac death risk post-LAD angioplasty; hypothesis-generating and requires prospective validation.
BACKGROUND: Few studies with large sample sizes are available regarding patients with Wellens' syndrome. Therefore, we sought to assess the current incidence, risk factors, clinical presentation and long-term outcomes of this population. METHODS: Among a total of 3528 patients with ACS who underwent angioplasty from 2017 to 2019 in our centre, 2127 NSTE-ACS patients with culprit LAD vessels were enrolled in this study. According to electrocardiographic criteria, the patients were divided into a Wellens' group (n = 200) and non-Wellens' group (n = 1927). The primary endpoint was cardiac death; the secondary endpoint was MACCE, a composite of all-cause death, cardiac death, recurrent myocardial infarction, target lesion revascularization, heart failure and stroke. RESULTS: The incidence of Wellens' syndrome was 5.7% (200 of 3528) of all ACS patients. Wellens' syndrome more often manifested as NSTEMI (69% vs. 17.5%, P < 0.001). The percentages of preexisting coronary heart disease (39.6% vs. 23%) and previous PCI (19.5% vs. 9%) were significantly higher in the non-Wellens' group than in the Wellens' group (all P < 0.001). More importantly, the proportion of early PCI was higher in the Wellens' group (68% vs. 59.3%, P = 0.017). At a median follow-up of 24 months, Wellens' syndrome was not associated with an increased risk of MACCE (P = 0.05) or cardiac death (P = 0.188). CONCLUSIONS: The presence of Wellens' syndrome is not definitively associated with adverse prognosis in patients with NSTE-ACS. Age ≥ 65 years, diabetes, NSTEMI, eGFR < 60 ml/min and left main disease are associated with the incidence of cardiac death. Early recognition and aggressive intervention are critical, as they may help to attenuate adverse outcomes.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: